84608 Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices 

1Title XXXIII of the PHS Act is codified at 42 

U.S.C. 300mm–300mm–64. Those portions of the 

Zadroga Act found in Titles II and III of Public Law 

111–347 do not pertain to the WTC Health Program 

and are codified elsewhere. 

2The List of WTC-Related Health Conditions is 

established in 42 U.S.C. 300mm–22(a)(3)–(4) and 

300mm–32(b); additional conditions may be added 

through rulemaking and the complete List is 

provided in WTC Health Program regulations at 42 

CFR 88.15. 

• By Mail: NIOSH Docket Office, 

Robert A. Taft Laboratories, MS C–34, 

1090 Tusculum Avenue, Cincinnati, 

Ohio 45226–1998. 

Instructions: All written submissions 

received in response to this notice must 

include the agency name (Centers for 

Disease Control and Prevention, HHS) 

and docket number (CDC–2024–0082; 

NIOSH–354) for this action. All relevant 

comments, including any personal 

information provided, will be posted 

without change to http://

www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Rachel Weiss, Program Analyst, 1090 

Tusculum Avenue, MS: C–48, 

Cincinnati, OH 45226; telephone (404) 

498–2500 (this is not a toll-free 

number); email NIOSHregs@cdc.gov. 

SUPPLEMENTARY INFORMATION: Title I of 

the James Zadroga 9/11 Health and 

Compensation Act of 2010 (Zadroga 

Act) (Pub. L. 111–347, as amended by 

Pub. L. 114–113, Pub. L. 116–59, Pub. 

L. 117–328, and Pub. L. 118–31), added 

Title XXXIII to the Public Health 

Service Act (PHS Act),1 establishing the 

WTC Health Program within HHS. The 

WTC Health Program provides medical 

monitoring and treatment benefits for 

health conditions on the List 2 to eligible 

firefighters and related personnel, law 

enforcement officers, and rescue, 

recovery, and cleanup workers who 

responded to the September 11, 2001, 

terrorist attacks in New York City, at the 

Pentagon, and in Shanksville, 

Pennsylvania (responders). The Program 

also provides benefits to eligible persons 

who were present in the dust or dust 

cloud on September 11, 2001, or who 

worked, resided, or attended school, 

childcare, or adult daycare in the New 

York City disaster area (survivors). 

The Zadroga Act also requires that the 

Program conduct or support research on 

health conditions that may result from 

the September 11, 2001, terrorist 

attacks, addressing the following topics: 

• Physical and mental health 

conditions that may be related to the 

September 11, 2001, terrorist attacks; 

• Diagnosing WTC-related health 

conditions for which there have been 

diagnostic uncertainty; and 

• Treating WTC-related health 

conditions for which there have been 

treatment uncertainty. 

For more information on NIOSHfunded research projects related to the 

September 11, 2001, terrorist attacks, 

and areas of interest based on the 

Program’s Research Agenda, please visit 

the WTC Health Program Research web 

page (https://www.cdc.gov/wtc/ 

research.html). 

Request for Information 

To further relevant WTC Health 

Program research in FY2026, NIOSH has 

forecasted two notices of funding 

opportunities: (1) RFA–OH–26–001: 

Cooperative Research Agreements 

Related to the World Trade Center 

Health Program (https://grants.gov/ 

search-results-detail/356163) and (2) 

RFA–OH–26–002: Assessment and 

Evaluation of Emerging Health 

Conditions Relevant to the World Trade 

Center Health Program (https://

grants.gov/search-results-detail/ 

356164). 

NIOSH seeks to achieve a suitable mix 

of meritorious research projects which 

assess the feasibility of new ways to 

enhance interventions and program 

evaluations with the potential to 

improve WTC Health Program treatment 

and care, and the overall well-being of 

9/11-exposed populations. Clinical 

research areas of interest include 

methods, interventions, or procedures 

which can improve the screening, 

diagnosis, and treatment of WTC-related 

health conditions and care for those 

exposed. NIOSH expects that such 

clinical research outcomes will 

incorporate relevant epidemiological 

aspects and use research results to 

improve treatment and care. Assessment 

and evaluation of treatment and care 

programs for WTC-related health 

conditions and exposed populations are 

also of interest. Additional details are 

provided in the forecasts for these 

proposed funding opportunities (please 

refer to the links included in this 

notice). 

Specifically, NIOSH seeks input on 

research priorities with regard to the 

following questions: 

(1) What are the primary research 

needs for the 9/11-exposed population, 

such as WTC responders, screeningeligible WTC survivors, or certifiedeligible WTC survivors? 

(2) What are the primary health 

concerns that are potentially related to 

9/11 exposure, or the treatment thereof, 

and how do they differ among groups 

within the 9/11-exposed population? 

(3) What emerging health conditions 

that may be related to 9/11 exposure 

should be prioritized and addressed? 

John J. Howard, 

Administrator, World Trade Center Health 

Program and Director, National Institute for 

Occupational Safety and Health, Centers for 

Disease Control and Prevention, Department 

of Health and Human Services. 

[FR Doc. 2024–24486 Filed 10–22–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Tribal Request for Reconsideration 

Hearing 

AGENCY: Office of Child Care; 

Administration for Children and 

Families; U.S. Department of Health and 

Human Services. 

ACTION: Notice of request for 

reconsideration hearing. 

SUMMARY: Notice is hereby given to the 

Inter-Tribal Council of Nevada (ITCN) 

and interested parties of a 

reconsideration hearing. The purpose of 

the hearing is to reconsider the decision 

of the Administration for Children and 

Families (ACF), Office of Child Care 

(OCC) regarding revision to the FY2023– 

2025 triennial child count submitted by 

the Inter-Tribal Council of Nevada 

(ITCN) as part of their triennial plan, 

submitted on July 1, 2022. Because the 

child count was submitted as part of 

ITCN’s FY2023–205 triennial plan, 

ITCN is entitled to request 

reconsideration to determine ‘‘whether 

such Plan or amendment conforms to 

the requirements for approval under the 

Act and pertinent Federal regulations.’’ 

The sole issue to be reconsidered is 

OCC’s decision to reduce ITCN’s child 

count. 

DATES: December 3, 2024, at 9:00 a.m. 

PST; 12:00 EST. 

ADDRESSES: Virtual via Zoom; Interested 

parties must submit a request for a 

registration link to Latasha Abney, 

Director, ACF Office of Grants Policy 

latasha.abney@acf.hhs.gov. 

FOR FURTHER INFORMATION CONTACT: 

Latasha Abney, Director, ACF Office of 

Grants Policy latasha.abney@

acf.hhs.gov or (202) 401–5324. 

SUPPLEMENTARY INFORMATION: By letter 

dated January 17, 2023, OCC 

communicated its decision that ITCN 

had submitted a duplicated child count 

in an area that overlapped the service 

area of another CCDF tribal lead agency, 

and that the area was not within a 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices 84609 

reasonably close geographic proximity 

to the delineated borders of one of 

ITCN’s member tribes, as required in 45 

CFR 98.61(c) and 98.83(b), and as 

described in the Program Instruction 

CCDF–ACF–PI–2022–03. As a result, 

OCC adjusted ITCN’s child count 

downward. 

CCDF regulations prescribe that 

reconsideration shall be conducted by 

hearing governed by 45 CFR part 99. 

The ACF Director of Office of Grants 

Policy, Latasha Abney, is the designated 

presiding officer. The presiding officer 

has authority to ‘‘modify or waive any 

rule in [Part 99] upon determination 

that no party will be unduly prejudiced 

and the ends of justice will thereby be 

served.’’ 45 CFR 99.4. 

45 CFR 99.15 allows recognition of 

other individuals or groups as parties ‘‘if 

the issues to be considered at the 

hearing have directly caused them 

injury and their interests to be protected 

by the governing Federal statute and 

regulations.’’ This Federal Register 

notice serves as notification to other 

parties who may have interest in this 

hearing. Individuals or groups desiring 

to participate as parties should submit 

a petition in writing to presiding officer, 

Latasha Abney, at the address above 

within 15 days of publication of this 

notice. Such petition shall concisely 

state (i) Petitioner’s interest in the 

proceeding; (ii) Who will appear for 

petitioner; (iii) The issues on which 

petitioner wishes to participate; and (iv) 

Whether petitioner intends to present 

witnesses. A copy of the petition must 

also be served on ITCN Executive 

Director, Deserea Quintana at 

dquintana@itcn.org. The presiding 

officer will promptly determine whether 

each petitioner has the requisite interest 

and shall permit or deny participation 

accordingly. 

45 CFR 99.22 allows parties to (a) 

Appear by counsel or other authorized 

representative, in all hearing 

proceedings; (b) Participate in any 

prehearing conference held by the 

presiding officer; (c) Agree to 

stipulations as to facts which will be 

made a part of the record; (d) Make 

opening statements at the hearing; (e) 

Present relevant evidence on the issues 

at the hearing; (f) Present witnesses who 

then must be available for crossexamination by all other parties; (g) 

Present oral arguments at the hearing; 

and (h) Submit written briefs, proposed 

findings of fact, and proposed 

conclusions of law, after the hearing. 45 

CFR 99.23 allows that ‘‘The Department, 

the Lead Agency, and any individuals or 

groups recognized as parties shall have 

the right to conduct discovery 

(including depositions) against 

opposing parties,’’ and that Rules 26–37 

of the Federal Rules of Civil Procedure 

shall apply to discovery proceedings. 

Pursuant to 45 CFR 99.32, at the 

conclusion of the hearing and 

completion of post-hearing briefs, if any, 

the presiding officer shall certify the 

record and provide recommended 

finding and a proposed decision to the 

Assistant Secretary. Any party will then 

have 20 days to file exceptions and a 

supporting brief or statement with the 

Assistant Secretary. The decision of the 

Assistant Secretary shall be the final 

agency action on the matter. 

All written material provided by ACF, 

ITCN, and any other recognized party 

will be included in the administrative 

record. 

Megan E. Steel, 

ACF Certifying Officer. Administration for 

Children and Families. 

[FR Doc. 2024–23441 Filed 10–22–24; 8:45 am] 

BILLING CODE 4184–87–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Notice of Interest Rate on Overdue 

Debts 

Section 30.18 of the Department of 

Health and Human Services’ claims 

collection regulations (45 CFR part 30) 

provides that the Secretary shall charge 

an annual rate of interest, which is 

determined and fixed by the Secretary 

of the Treasury after considering private 

consumer rates of interest on the date 

that the Department of Health and 

Human Services becomes entitled to 

recovery. The rate cannot be lower than 

the Department of Treasury’s current 

value of funds rate or the applicable rate 

determined from the ‘‘Schedule of 

Certified Interest Rates with Range of 

Maturities’’ unless the Secretary waives 

interest in whole or part, or a different 

rate is prescribed by statute, contract, or 

repayment agreement. The Secretary of 

the Treasury may revise this rate 

quarterly. The Department of Health and 

Human Services publishes this rate in 

the Federal Register. 

The current rate of 123⁄8%, as fixed by 

the Secretary of the Treasury, is certified 

for the quarter ended September 30, 

2024. This rate is based on the Interest 

Rates for Specific Legislation, ‘‘National 

Health Services Corps Scholarship 

Program (42 U.S.C. 254o(b)(1)(A))’’ and 

‘‘National Research Service Award 

Program (42 U.S.C. 288(c)(4)(B)).’’ This 

interest rate will be applied to overdue 

debt until the Department of Health and 

Human Services publishes a revision. 

David C. Horn, 

Director, Office of Financial Policy and 

Reporting. 

[FR Doc. 2024–24510 Filed 10–22–24; 8:45 am] 

BILLING CODE 4150–04–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Feasibility of Novel 

Diagnostics for TB in Endemic Countries 

(FEND for TB) (R01—Clinical Trial Not 

Allowed). 

Date: November 22, 2024. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3E72A, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Frank S. De Silva, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3E72A, Rockville, MD 

20892, (240) 669–5023, fdesilva@

niaid.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24543 Filed 10–22–24; 8:45 am] 

BILLING CODE 4140–01–P 


khammond on DSKJM1Z7X2PROD with NOTICES